Interní Med. 2019; 21(1): 24-27 | DOI: 10.36290/int.2019.004

Overview of drug interactions of direct oral antikoagulants

MUDr. Katarína Bielaková, PhD., prof. Hana Matějovská Kubešová, CSc.
Klinika interní, geriatrie a praktického lékařství FN Brno Bohunice

For many years, the vitamin K anatagonists were the only available oral antikoagulants. This situation changed with the introduction
of new oral antikoagulants. The antikoagulant effect of this new group is less influenced by interactions with foods,
prescribed drugs and other over-the-counter medications than the vitamin K antagonists. However, drug interactions must still
be considered with the use of direct oral antikoagulants (DOAC). We present potential interactions in this review paper.

Keywords: coagulation, direct oral antikoagulants, drugs interactions, dabigatran, rivaroxaban, edoxaban, apixaban

Published: February 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bielaková K, Matějovská Kubešová H. Overview of drug interactions of direct oral antikoagulants. Interní Med. 2019;21(1):24-27. doi: 10.36290/int.2019.004.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Michalcová J, Penka M, Buliková A, et al. Nová - přímá perorální antikoagulancia: aktuální přehled. Vnitř Lék 2016; 62(10): 805-813. Go to PubMed...
    2. Květina J, Grudmann M. Farmakologické interakce. Klin Farmakol Farm 2003: 17(1): 17-21.
    3. SÚKL. http://www.sukl.cz/sukl/informacni-zpravodaj-nezadouci-ucinky-leciv-1-2017
    4. Kvasnička T. Dabigatran - klinické důkazy pro léčbu pacientů s TEN. Klin farmakol Farm 2016; 30(3): 15-17. Go to original source...
    5. Urbánek K. Klinická farmakologie přímých perorálnich antikoagulancií. Acta medicinae 2016; 5(10): 29-34.
    6. Di Minno A, Frigerio B, Spadarella G et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017; 31(4): 193-203. Go to original source... Go to PubMed...
    7. The European Medicines Agency. Souhrn o přípravku Pradaxa. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf
    8. Burdová K. Přímá perorální antikoagulancia. Klin farmakol Farm 2015; 29(4): 138-143.
    9. Prokeš M, Suchopár J. Lékové interakce nových orálních antikoagulancií. Practicus 2015; 14 (6): 14-21.
    10. The European Medicines Agency. Souhrn o přípravku Xarelto. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
    11. Souček M. Apixaban má komplexní spektrum indikací. Farmakoterapie, Praha: Farmakon Press, 2015, roč. 2015, č. 1, 104-108.
    12. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010; 38(3): 448-458. Go to original source... Go to PubMed...
    13. The European Medicines Agency. Souhrn o přípravku Eliquis. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf
    14. Kvasnička J. Edoxaban-nový inhibitor FXa. Remedia 2017; 27(2): 120-126.
    15. Samama MM, Mendell, J, Guinet, C et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res 2012; 129(4): e77-e82. Go to original source... Go to PubMed...
    16. Špinar J, Vítovec J. Edoxaban v klinických studiích a klinické praxi. Remedia 2016; 26 (4): 345-348.
    17. The European Medicines Agency. Souhrn o přípravku Lixiana. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.